1  BACKGROUND INFORMATION ON THE PROCEDURE 
1.1  Submission of the dossier 
The  applicant  Schering-Plough  Europe  submitted  on  06  October  2005  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Suboxone,  through  the  centralised 
procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised 
procedure was agreed upon by the EMEA/CHMP on 15 December 2004.  
The legal basis for this application refers to:  
Article 10(b) of Directive 2001/83/EC, as amended – relating to applications new fixed combination 
products. 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
Suboxone has been given a Marketing Authorisation in the United States of America in October 2002, 
in New Zealand in January 2005 and in Australia in July 2005. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Dr Karl Broich  Co-Rapporteur: Dr Patrick Salmon 
Rapporteur: 
1.2  Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 06 October 2005.  
The procedure started on 26 October 2005. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 05 January 
2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  
9 January 2006. 
During  the  meeting  on  20-23  February  2006,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  24 February 2006. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 02 June 
2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 26 May 2006. 
During  the  CHMP  meeting  on  26-28  June  2006,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing and in an oral explanation by the applicant. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Outstanding Issues to all CHMP members on 18 July 2006. 
During the meeting on  24-27 July 2006, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Suboxone  on  27  July  2006.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 26 July 2006. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 26 September 2006. 
© EMEA 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
